← Back to Search

Antiplatelet Agent

Aspirin for Hypertrophic Cardiomyopathy (TROPHIC 3 Trial)

Phase 3
Waitlist Available
Led By Aun-Yeong Chong, MD, MRCP
Research Sponsored by Ottawa Heart Institute Research Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 hour, 1 hour, 6 hours, 24 hours 72 hours and 7 days
Awards & highlights

TROPHIC 3 Trial Summary

This trial suggests that aspirin may inhibit the mobilization of EPCs, which could have implications for its use during acute myocardial infarction.

Eligible Conditions
  • Hypertrophic Cardiomyopathy

TROPHIC 3 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 hour, 1 hour, 6 hours, 24 hours 72 hours and 7 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 hour, 1 hour, 6 hours, 24 hours 72 hours and 7 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum circulating endothelial progenitor cells as a ratio to baseline at any timepoint
Secondary outcome measures
Endothelial cell migration in vitro compared to baseline at any timepoint
Other outcome measures
Peak SDF-1 level
Peak angiopoietin-1 level
Peak angiopoietin-2 level
+2 more

TROPHIC 3 Trial Design

2Treatment groups
Active Control
Group I: AspirinActive Control1 Intervention
Aspirin 325mg orally bolus followed by 162mg orally daily during alcohol septal ablation for hypertrophic obstructive cardiomyopathy until day 7.
Group II: No aspirinActive Control1 Intervention
No aspirin allowed during alcohol septal ablation for hypertrophic obstructive cardiomyopathy until day 7.

Find a Location

Who is running the clinical trial?

Ottawa Heart Institute Research CorporationLead Sponsor
188 Previous Clinical Trials
92,430 Total Patients Enrolled
Aun-Yeong Chong, MD, MRCPPrincipal InvestigatorOHIRC

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the Aspirin FDA status?

"Aspirin is a well-known medication, so it received a score of 3."

Answered by AI

Are investigators looking for participants who are over 30 years old for this trial?

"According to the study's inclusion criteria, patients aged 18 to 80 are eligible to apply. In contrast, there are 45 clinical trials specifically for minors and 374 for seniors."

Answered by AI

What is a common reason that people take Aspirin?

"Aspirin is a medication with many applications. In the context of percutaneous coronary intervention (pci), it is used as a treatment. It can also help with dental procedures, inflammation, and neck pain."

Answered by AI

What other similar medical trials exist for this purpose?

"Aspirin has been the focus of medical research since 2002. The first clinical trial was sponsored by Sanofi and was conducted in 2002 with 413 patients. As a result of the study, Aspirin was approved for Phase 3 drug trials. Currently, there are 181 active studies being conducted in 1451 cities and 61 countries."

Answered by AI

What is the projected enrollment for this clinical trial?

"That is correct. The latest information from clinicaltrials.gov suggests that this study is still recruiting patients. The trial began on May 1st, 2016 and the investigators are looking for 20 more participants. There is only 1 recruitment site."

Answered by AI
Recent research and studies
Thrombosis ResearchJournal
The Effect of Aspirin on Endothelial Progenitor Cell Biology: Preliminary Investigation of Novel Properties
Lou, Junyang, Thomas J. Povsic, Jason D. Allen, Stacie D. Adams, Shelley Myles, Aijing Z Starr, Thomas L. Ortel, and Richard C. Becker. 2010. “The Effect of Aspirin on Endothelial Progenitor Cell Biology: Preliminary Investigation of Novel Properties”. Thrombosis Research. Elsevier BV. doi:10.1016/j.thromres.2009.11.017.
Acta Pharmacologica SinicaJournal
Effects of Aspirin on Number, Activity and Inducible Nitric Oxide Synthase of Endothelial Progenitor Cells from Peripheral Blood1
CHEN, Tu-gang, Jun-zhu CHEN, and Xu-dong XIE. 2006. “Effects of Aspirin on Number, Activity and Inducible Nitric Oxide Synthase of Endothelial Progenitor Cells from Peripheral Blood1”. Acta Pharmacologica Sinica. Springer Science and Business Media LLC. doi:10.1111/j.1745-7254.2006.00298.x.
British Journal of PharmacologyJournal
Platelet-mediated Angiogenesis Is Independent of VEGF and Fully Inhibited by Aspirin
Etulain, J, C Fondevila, S Negrotto, and M Schattner. 2013. “Platelet-mediated Angiogenesis Is Independent of VEGF and Fully Inhibited by Aspirin”. British Journal of Pharmacology. Wiley. doi:10.1111/bph.12250.
clinicaltrials.govStudy
Mobilization of Endothelial Progenitor Cells and Aspirin
2016. "Mobilization of Endothelial Progenitor Cells and Aspirin". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02674958.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top